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Personalized medicine is emerging as a main paradigm for risk prediction,
pre-diagnosis, and effective prevention and treatment of disease. A large
number of human biospecimens and their clinical data are essential resources for
the success of personalized medicine as well as other biomedical research.
The National Biobank of Korea (NBK) has collected well-annotated and high
quality human biospecimens, and distributes them to the Korean biomedical
scientists, through the Korea Biobank Project (KBP). The ultimate goal of NBK
activities is to promote biomedical research and public health. As of December-
2011, the NBK has collected various human biospecimens from 525,416 partici-
pants including 325,952 Korean populations and 199,464 patients. The purpose of
this paper is to introduce the KBP and quality control programs for collection of
human biospecimens with high quality of NBK.1. Introduction
Worldwide many biobanks have collected, preserved,
and distributed a large number of human biospecimens
with high quality and their related information, which
can be widely used for various studies on diagnosis,
therapy, and prevention of diseases [1,2]. For example,
UK Biobank has collected blood and urine samples from
500,000 individual participants aged 40e69 to study
disease-associated lifestyle, environmental effects or
genetic factors [3]. In Norway, the biobank forted under the terms of the C
0) which permits unrestrict
roperly cited.
ase Control and PreventionNorwegian mother and child cohort study (MoBa) has
stored human biospecimens (such as whole blood,
plasma, DNA and urine) of pregnant women, their
partners and children collected at 50 hospitals [4]. In
Japan, the Biobank Japan Project has been performed for
collection of a large number of DNA and serum samples
with clinical information [5].
The National Biobank of Korea (NBK) has collected
various human biospecimens with high quality from
population-based participants and disease-based partic-
ipants through the Korea Biobank Project (KBP).reative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
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been collected by population-based cohort studies such
as Korean Genome and Epidemiology Study (KoGES),
the National Survey of Health and Nutrition, and other
government-supported survey projects. KoGES is
a project with the aim of collecting human biospecimens
(such as whole blood, serum, plasma, urine, and blood
DNA) and health associated information from over
300,000 participants aged 40e69 to support the studies
for the relationships between genetic background,
environmental risk factors, and lifestyle and disease
development in individuals and populations. Human
biospecimens from disease-based participants have been
collected through 17 regional biobanks of university
hospitals in Korea. These collected human biospecimens
have been distributed to internal scientists to promote
biomedical studies and public health.
The objectives of this paper are to describe
a summary of the KBP and introduce biobank activity of
the NBK to collect a great many human biospecimens
with high quality.2. Activities of the National Biobank of
Korea
2.1. Korea Biobank Project
The KBP was launched in 2008, which has been
conducted by the NBK. The first phase of KBP aims to
collect human biospecimens from 500,000 participants
(including 300,000 population-based participants and
200,000 disease-based participants) with their epidemi-
ological and clinical information until 2012. The NBK
has collected and distributed a large number of human
biospecimens from population-based participants and
disease-based participants since 2001 and 2008,
respectively. As of December-2011, the NBK has
collected human biospecimens from 525,416 partici-
pants including 325,952 Korean populations and
199,464 patients. Population-based biospecimens
included 2,078,544 (40%) serum, 1,953,270 (37%)
plasma, 801,309 (15%) DNA, and 435,593 (8%) other
biospecimens. Disease-based biospecimens contained
1,274,313 (50%) plasma, 568,041 (22%) serum, 222,872
(9%) tissue, 143,667 (6%) buffy coat, and 318,559
(13%) other biospecimens.
For KBP, the NBK has appointed and supported
regional biobanks which collect disease-based human
biospecimens. In 2008, the NBK appointed eight
regional biobanks and increased up to 17 in 2012.
Collected human biospecimens and their related infor-
mation have been shared through the web-based Korea
Biobank Network (KBN) system. This system is
continuously developing to provide much more infor-
mation for many scientists. The NBK has distributed
collected human biospecimens to internal scientists to
support various studies including translational researchand personalized medicine. Especially, the NBK has
supported the Korean Genome Analysis Project
(KoGAP) which aims to identify genetic and environ-
mental risk factors leading the development of the five
common life-style-related diseases such as obesity,
diabetes, hypertension, osteoporosis, and metabolic
syndrome in a large number of Korean populations.
2.2. Quality control programs of human
biospecimens
Quality of human biospecimens collected in NBK has
been controlled by following guidelines. DNA samples
must have the purity and integrity, and be adjusted to
500 ng of DNA per 1 ml. LCL samples must have a high
viability and be not contaminated by microorganism. In
addition, all human biospecimens must be stored and
transported on frozen condition. The NBK performs
quality test of collected human biospecimens and then
those with high quality are only stored in deep freezer
(80 C) (DNA, whole blood, and urine) or liquid
nitrogen tank (serum, plasma, lymphocyte, and LCL).2.2.1. Quality control of DNA
Generally, spectrophotometric method has used for
quantity and quality evaluation of nucleic acids
including DNA and RNA. DNA and RNA have the
maximum absorption at approximately 260 nm and
protein absorbs strongly at near 280 nm. Contaminants
such as EDTA, carbohydrates and phenol have absorp-
tion at near 230 nm. Therefore, A260/A280 and A260/
A230 ratio show the purity degree of nucleic acids.
DNA sample has been considered as pure if A260/A280
ratio is from 1.8 to 2.0 and A260/A230 ratio is over 2.0.
However, DNA sample with lower A260/A230 ratio
(1.7  A260/A230 ratios < 2.0) can be used for
molecular biology experiments. Concentration of DNA
(microgram/mL) is calculated as 50  OD260 of the
sample. Fluorochromes such as PicoGreen, Hoechest
33258, and SYBR Green Ⅰ have been used to evaluate
the quantity of double strand DNA selectively. Among
them, DNA quantitation using PicoGreen which has an
excitation maximum at 480 nm and an emission
maximum at 520 nm is best sensitive and simple [6].
Limitation of DNA quantitation of PicoGreen assay is
0.25 ng of DNA per 150 mL of assay volume [6]. DNA
integrity has generally been measured by two techniques
including gel electrophoresis and PCR analysis [7,8]. In
gel electrophoresis, DNA degradation is shown by
double or smeared band compared with molecular
weight marker of DNA. DNA quality can be also
determined by yield of PCR amplicon.
In the NBK, quality of collected DNA has been tested
with aliquot of each sample divided in clean bench.
DNA integrity has been assessed through gel electro-
phoresis because can detect the tiny DNA degradation
and measure the approximate quantity. DNA purity has
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(using NanoDrop machine) with advantage which can
measure purity (A260/A280 ratio and A260/A230 ratio)
and concentration (OD260) at the same time. Microbial
(bacteria and mycoplasma) contamination has deter-
mined with each microbial specific primers (16S rRNA
primers) using PCR method. In case of blood DNA,
approximately ten percent which randomly selected in
all collected blood DNA samples are used for test.
Quality of LCL DNA is evaluated in all collected
samples. DNA integrity is determined by the absence of
a smeared or double band on gel electrophoresis and the
standard of DNA purity is an A260/A230 ratio 1.8 and
1.8  A260/A280 ratio  2.0. PicoGreen analysis is
performed when DNA degradation is observed on gel
electrophoresis. Microbial contamination is determined
by the presence of DNA band in gel electrophoresis of
PCR amplicon.
2.2.2. Quality control of lymphoblastoid cell line
Lymphoblastoid cell lines (LCLs) are a research
model which widely used in various studies. Quality
control of LCLs is important for an exact experimental
result. Generally, cell quality is assessed on viability,
authentication, and microbial contamination. Cell
viability shows proliferative capacity. Authentication
test is performed to identify whether cross-
contamination is or not, using morphology observa-
tion, karyotyping, DNA typing, or immunophenotyping.
All cultured cells are often contaminated by various
microorganisms such as bacteria (including myco-
plasma), yeast, and fungi during cultivation [9]. Among
them, the most commune contaminates are mycoplasma
[10e12] and other bacteria from human skin and air
[10,11]. Microbial contamination in cells can influence
cell morphology, differentiation state, and gene
expression. Bacteria, yeast and fungi contaminations are
simply detected by macroscopy during cultivation
process however detection of viruses, protozoa and
mycoplasma is difficult [13].
In the NBK, quality of LCLs has been assessed on
bacterial and mycoplasma contamination and cell
viability (number of live cells/number of total
cells  100) in approximately 10% randomly selected in
all collected LCLs. A contamination test is carried out
through macroscopy during cultivation and PCR
experiment. In PCR experiments, DNA samples
extracted from LCLs are amplified with each microbial
specific primer (16S rRNA primers) and amplicon is
detected on gel electrophoresis. The LCLs must be over
50% of cell viability and without contamination.
2.2.3. STR analysis
Short tandem repeats (STRs) are repeating DNA
sequences with 2-6 bp length per a unit [14] that exist
generally in eukaryotes (including human) and
prokaryotes [15]. Most STRs exist on non-coding regionand approximately 8% of STRs exist on coding region
[16]. Analysis of STR has been used widely in various
fields, including forensic identification, population-
based genetic study, and identification of disease-
associated genetic alteration.
In the NBK, STR analysis has been performed for
DNA identification using commercial kit analyzing 15
STR loci (CSF1P0, D2S1338, D3S1358, D5S818,
D7S820, D8S1179, D13S317, D16S539, D18S51,
D19S433, D21S11, FGA, TH01, TPOX, and vWA) and
Amelogenin, the gender marker. STR data have been
used as a yardstick of judgment to check whether the
cross-contamination between samples was happened or
not. In addition, these information have been used for
comparison with sex information in donor’s epidemio-
logical and clinical information. As of December-2011,
STR analysis has been carried out with about 25,342 of
blood DNA and LCL DNA.
2.2.4. Contamination assessment of liquid nitrogen
tank
The liquid nitrogen tank can be contaminated by
microorganisms when biospecimens have been stored
for a long time. Indeed, other researchers investigated
microbial contamination of embryos and semen samples
stored for 6-35 years in 16 liquid nitrogen tanks. The
results showed that different commensal or environ-
mental microorganisms (32 bacteria and 1 fungi) was
contaminated in liquid nitrogen, embryos, and semen
samples [17]. Microbial contamination can be happened
by ice accumulation in a liquid nitrogen tank [18]. This
ice accumulation can be made by falling of ice forming
in atmosphere when a liquid nitrogen tank opens. Ice
formation on cold surface of tank, rack or sample box
can also be a cause of microbial contamination in the
liquid nitrogen tank.
The NBK has investigated microbial contamination
of liquid nitrogen tanks using Bielanski’s method [17]
every year since 2005 (data not shown).
2.2.5. Quality control of human biospecimens in
regional biobanks
The NBK has recommended that regional biobanks
should perform quality tests of human biospecimens
collected from patients. The quality test is carried out as
follows: For quality control of fresh frozen tissues, RNA
samples are extracted from >3% of collected all tissues.
Subsequently, the concentration of RNA samples are
evaluated by spectrophotometric method and the integ-
rity of these are assessed by gel electrophoresis and
measurement of RNA integrity number.
2.2.6. Other activities
The quality of collected human biospecimens has
managed by other various efforts of the NBK. For
example, ISO 9001:2008 was implemented for the
188 J.-E. Lee, et alcollection, preservation, and distribution of human bio-
specimens (such as DNA, cell, serum, and urine) through
the Korean Standard Association. Standard Operation
Protocols (SOPs) were made for the collection, preser-
vation and distribution of human biospecimens at first
time in 2008 and annually edited to produce the best
practice SOPs [19]. For systematic storage management,
automated biospecimens management platform [20] was
equipped in 2009 and 300,000 vials of DNA is storing at
this platform with 80 C condition.
2.3. Study for characteristics of human
biospecimens
Many scientists in the NBK have been studying on
various factors influencing the quality of human speci-
mens and the effects of them on experimental data, to
manufacture the best practice SOPs for human bio-
specimens collection with high quality. For examples,
we investigated an influence of bacterial DNA
contamination in blood DNA on SNP chip data. The
result showed that there is no correlation [21]. We also
are studying on the effect of the delay of plasma isola-
tion from whole blood sample on biochemical expres-
sion (In preparation for publication). To make better use
of LCLs in research, we have studied their characteris-
tics. LCLs have been used in various research fields
such as pharmacogenomics, human genetics, and
immunology. However, there is some concern about the
wide use of LCLs because genetic alterations can be
occurred by EBV-transformation during generation or
immortalization of LCLs. To identify expression
phenotype change associated with immortalization of
LCLs, we performed a continuous long-term culture
with 20 LCLs strains [22] and then identified phenotype
changes of genes [23] and miRNAs [24] during long-
term cultivation of LCLs, through microarray
approach. Fifty genes including NF-kB pathway-related
genes (e.g. PTPN1 and HERC5) and carcinogenesis-
related genes (e.g. XAF1, TCL1A, PTPN13, and
CD38) commonly showed the different expression in
most of all tested late-passage LCLs compared with
early-passage LCLs. Nine miRNAs (miR-20b*, miR-28-
5p, miR-99a, miR-125b, miR-151-3p, miR-151:9.1,
miR-216a, miR-223*, and miR-1296) were differently
expressed during long-term culture of LCLs. Copy
numbers changes of DNA were investigated in early
passage LCLs compared with primary B cells. The
result revealed that DNA alterations were not observed
in the most of tested regions [25]. We also identified that
expression of STMN1, an oncogene, was increased in
early passage LCLs compared to primary B cells [26].3. Conclusion
The NBK has conducted the KBP with aim of human
biospecimens collection from 300,000 population-basedparticipants and 200,000 disease-based participants until
2012. Population-based human biospecimens have
collected through government supported cohort studies.
Disease-based human biospecimens have collected
through 17 regional biobanks which appointed and
supported by the NBK.
The collected human biospecimens have been
managed by different quality control programs and their
characteristics have been studied to increase the value of
human biospecimens. Ultimately, these efforts of the
NBK would contribute to identification of new scientific
facts for promotion of health of many people.Acknowledgement
This study was supported by an intramural grant
(091-4800-4851-307-210) of Korea National Institute of
Health.
References
1. Davey Smith G, Ebrahim S, Lewis S, et al. Genetic epidemiology
and public health: hope, hype, and future prospects. Lancet 2005
Oct 22-28;366(9495):1484e98.
2. Patel AA, Gilbertson JR, Parwani AV, et al. An informatics model
for tissue banks-lessons learned from the cooperative prostate
cancer tissue resource. BMC Cancer 2006 May 5;6:120.
3. Elliott P, Peakman TC. The UK Biobank sample handling and
storage protocol for the collection, processing and archiving of
human blood and urine. Int J Epidemiol 2008 Apr;37(2):234e44.
4. Rønningen KS, Paltiel L, Meltzer HM, et al. The biobank of the
Norwegian mother and child cohort study: a resource for the next
100 years. Eur J Epidemiol 2006;21(8):619e25.
5. Nakamura Y. The BioBank Japan Project. Clin Adv Hematol
Oncol 2007 Sep;5(9):696e7.
6. Ahn SJ, Costa J, Emanuel JR. PicoGreen quantitation of DNA:
effective evaluation of samples pre- or post-PCR. Nucleic Acids
Res 1996 Jul 1;24(13):2623e5.
7. FeigelsonHS,RodriguezC,RobertsonAS, et al.Determinants ofDNA
yield and quality from buccal cell samples collected with mouthwash.
Cancer Epidemiol Biomarkers Prev 2001 Sep;10(9):1005e8.
8. Zayats T, Young TL, Mackey DA, et al. Quality of DNA extracted
from mouthwashes. PLoS One 2009 Jul 7;4(7):e6165.
9. Cobo F, Stacey GN, Hunt C, et al. Microbiological control in stem
cell banks: approaches to standardisation. Appl Microbiol
Biotechnol 2005 Sep;68(4):456e66.
10. Halls N. Effects and causes of contamination in sterile
manufacturing. In: Halls N, editor. Microbiological contamination
control in pharmaceutical clean rooms. Boca Raton (FL): CRC
Press; 2004. p. 1e22.
11. Owers KL, James E, Bannister GC. Source of bacterial shedding
in laminar flow theatres. J Hosp Infect 2004 Nov;58(3):230e2.
12. Uphoff CC, Drexler HG. Detection of mycoplasma contamina-
tions. Methods Mol Biol 2005;290:13e23.
13. Ryan J. Understanding and managing cell culture contamination.
Technical Bulletin. Corning Life Sciences; 2002.
14. Kimpton C, Gill P, D’Aloja E, et al. Report on the second EDNAP
collaborative STR exercise. European DNA Profiling Group.
Forensic Sci Int 1995 Jan 30;71(2):137e52.
15. Fan H, Chu JY. A brief review of short tandem repeat mutation.
Genomics Proteomics Bioinformatics 2007 Feb;5(1):7e14.
16. Ellegren H. Heterogeneous mutation processes in human
microsatellite DNA sequences. Nat Genet 2000 Apr;24(4):400e2.
Quality control programs 18917. Bielanski A, Bergeron H, Lau PC, et al. Microbial contamination
of embryos and semen during long term banking in liquid
nitrogen. Cryobiology 2003 Apr;46(2):146e52.
18. Morris GJ. The origin, ultrastructure, and microbiology of the
sediment accumulating in liquid nitrogen storage vessels. Cryo-
biology 2005 Jun;50(3):231e8.
19. National Biobank of Korea. Standard Operating Procedures for
Human Biospecimens; 2010.
20. Comley J. Automated biobanking-the next big step for bio-
respositories. Drug Discovery World Summer; 2007:49e70.
21. Lee JE, Hong EJ, Shim SM, et al. Bacterial contamination
of blood DNA samples is associated with donor’s health
condition. Biopreservation and Biobanking 2010 Sep 29;8(3):
127e31.
22. Jeon JP, Nam HY, Shim SM, et al. Sustained viral activity of
epstein-Barr virus contributes to cellular immortalization oflymphoblastoid cell lines. Mol Cells 2009 Feb 28;27(2):
143e8.
23. Lee JE, Nam HY, Shim SM, et al. Expression phenotype changes
of EBV-transformed lymphoblastoid cell lines during long-term
subculture and its clinical significance. Cell Prolif 2010 Aug;
43(4):378e84.
24. Lee JE, Hong EJ, Nam HY, et al. MicroRNA signatures associated
with immortalization of EBV-transformed lymphoblastoid cell
lines and clinical traits. Cell Prolif 2011 Feb;44(1):59e66.
25. Jeon JP, Shim SM, Nam HY, et al. Copy number increase of
1p36.33 and mitochondrial genome amplification in Epstein-Barr
virus-transformed lymphoblastoid cell lines. Cancer Genet
Cytogenet 2007 Mar;173(2):122e30.
26. Baik SY, Yun HS, Lee HJ, et al. Identification of stathmin 1
expression induced by Epstein-Barr virus in human B
lymphocytes. Cell Prolif 2007 Apr;40(2):268e81.
